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Impaired CD8+ T cell responses 
upon Toll-like receptor activation in common 
variable immunodeficiency
Camila de Lollo1, Dewton de Moraes Vasconcelos1, Luanda Mara da Silva Oliveira1, Tiago de Oliveira Titz1, 
Magda Carneiro‑Sampaio2, Cristina Miuki Abe Jacob2, Alberto José da Silva Duarte1 and Maria Notomi Sato1*
Abstract 
Background: Infections caused by bacteria or viruses are frequent in common variable immunodeficiency (CVID) 
patients due to antibody deficiencies, which may be associated with altered T cell function. CVID patients are fre‑
quently in contact with pathogen‑associated molecular patterns (PAMPs), leading to the activation of innate immu‑
nity through Toll‑like receptors (TLR) affecting T cell activation. We evaluated the effect of TLR activation on T cells in 
CVID patients undergoing intravenous immunoglobulin (IVIg) replacement using synthetic ligands.
Methods: Expression of exhaustion, activation and maturation markers on T cells from peripheral blood as well as 
regulatory T cells and follicular T cells in peripheral blood mononuclear cells (PBMCs) from CVID and healthy individu‑
als were evaluated by flow cytometry. PBMCs cultured with TLR agonists were assessed for intracellular IFN‑γ, TNF, 
IL‑10, IL‑17a or IL‑22 secretion as monofunctional or polyfunctional T cells (simultaneous cytokine secretion) by flow 
cytometry.
Results: We found increased expression of the exhaustion marker PD‑1 on effector memory CD4+ T cells 
(CD45RA−CCR7−) in the peripheral blood and increased expression of CD38 in terminally differentiated CD8+ T 
cells (CD45RA+CCR7−). Furthermore, a decreased frequency of naïve regulatory T cells (CD45RA+Foxp3low), but 
not of activated regulatory T cells (CD45RA−Foxp3high) was detected in CVID patients with splenomegaly, the non‑
infectious manifestation in this CVID cohort (43.7 %). Moreover, the frequency of peripheral blood follicular helper T 
cells (CD3+CD4+CXCR5+PD‑1+ICOS+) was similar between the CVID and control groups. Upon in vitro TLR3 activa‑
tion, a decreased frequency of CD8+ T cells secreting IFN‑γ, IL‑17a or IL‑22 was detected in the CVID group compared 
to the control group. However, a TLR7/TLR8 agonist and staphylococcal enterotoxin B induced an increased Th22/
Tc22 (IL‑22+, IFN‑γ−, IL‑17a−) response in CVID patients. Both TLR2 and TLR7/8/CL097 activation induced an increased 
response of CD4+ T cells secreting three cytokines (IL‑17a, IL‑22 and TNF)in CVID patients, whereas CD8+ T cells were 
unresponsive to these stimuli.
Conclusion: The data show that despite the unresponsive profile of CD8+ T cells to TLR activation, CD4+ T cells and 
Tc22/Th22 cells are responsive, suggesting that activation of innate immunity by TLRs could be a strategy to stimulate 
CD4+ T cells in CVID.
Keywords: Common variable immunodeficiency, Exhaustion and activation markers, Toll‑like receptor agonists, Tc22/
Th22, Polyfunctional T cells
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Background
Common variable immunodeficiency (CVID) is a pri-
mary immunodeficiency characterized by susceptibility 
to recurrent infections due to inadequate quantity and 
quality of protective antibodies [1]. There is an immense 
phenotypic heterogeneity of patients with CVID, which 
can be observed in the variability of the age at onset of 
disease and related comorbidities, including autoimmune 
diseases, malignancies, chronic lung diseases, spleno-
megaly and gastrointestinal diseases [2, 3]. The current 
treatment consists of intravenous IgG (IVIG) replace-
ment every 3–4  weeks [4] with the goal of protecting 
patients against infection by extracellular pathogens.
Relapsing bacterial/viral infections in CVID trigger 
strong stimulation of innate immunity. Upon pathogen-
associated molecular pattern (PAMP) expression, pattern 
recognition receptors (PRRs), including Toll-like recep-
tors (TLRs), trigger intracellular signals to innate immune 
cells to contain the infection and return to homeostasis 
[5]. However, defective TLR7 and TLR9 signaling in B 
cells and plasmacytoid dendritic cells (pDCs), deficient 
IFN-α secretion, and impaired B cell function alter innate 
immune responses in CVID, thus preventing TLR-medi-
ated enhancement of humoral immunity in  vivo and 
possibly increasing susceptibility to enteroviral and rhi-
noviral infections [6, 7].
Moreover, there are several CD4+ T cell abnormalities 
and functional alterations in CVID, such as a reduction 
in CD4+ T cell counts, reduced proliferation capacity 
and/or impaired cytokine production [2, 8–10]. Bacteria-
specific CD4+ T cells from CVID patients are function-
ally impaired and express high levels of programmed 
death 1 (PD-1) [11]. Intravenous immunoglobulin (IVIg) 
treatment significantly reduces endotoxemia and PD-1+ 
expression on CD4+ T cells, restoring bacteria-specific 
CD4+ T cell cytokine production and proliferation [11] 
and reducing CD8+ T cell activation [12].
Antigen-presenting cells have been the primary focus 
of TLR research, although TLRs are also expressed on 
cells of the adaptive immune system, such as T and B 
cells. Activation of TCR up-regulates TLR expression, 
rendering these T cells responsive to TLR agonists, such 
as TLR5 and TLR7/TLR8, which demonstrate co-stimu-
latory capacity [13, 14]. It has been suggested that TLR 
stimulation of T cells can function as a co-stimulator 
during the initiation of an adaptive immune response 
to aid the survival of memory T cells, as well as in the 
rapid induction of a memory response [15]. The T cell 
perturbations in CVID can be attenuated by IVIg treat-
ment, whereas the adjuvant role of TLR activation, 
which directly or indirectly influences CD4/CD8 T cell 
responses, could be of great interest.
In the present study, the results show the adjuvant role 
of TLR agonists in adaptive immunity, leading to a poly-
functional response primarily by CD4+ T cells and to 
increased Th22/Tc22 responses in CVID.
Methods
Patients
CVID patients were followed at the primary immuno-
deficiency diseases outpatient clinic (ADEE3003) of the 
Hospital das Clínicas, Faculdade de Medicina da Uni-
versidade de São Paulo (HC/FMUSP). The CVID group 
(n  =  16) consisted of 10 males and six females (aged 
22–65), and the healthy donors (n  =  16) consisted of 
seven males and nine females (aged 21–65). All CVID 
patients fulfilled the European society for immunode-
ficiencies (ESID) and Pan-American Group for Immu-
nodeficiency (PAGID) criteria [16], and all were on IVIg 
replacement at a dose of 400–800 mg/kg/3–4 weeks (to 
maintain trough levels above 8.0  g/L). Blood samples 
were collected before IVIg infusion; during this period, 
all patients were free of acute or chronic infections, and 
none was receiving corticosteroid therapy. The research 
involving human participants reported in this study was 
approved by the São Paulo University Institutional Use 
Committee. Study participants were enrolled after sign-
ing and dating an approved informed consent. Our Eth-
ics Committee approved the consent procedure. The 
approval number is (0295/09).
Flow cytometry in peripheral blood
To analyze the exhaustion/activation markers at differ-
ent stages of T cell maturation (naïve CCR7+ CD45RA+, 
effector CCR7−  CD45RA−, memory CCR7+  CD45RA−, 
memory RA CCR7− CD45RA+) in the peripheral blood, 
venous blood was collected in EDTA-anticoagulated 
tubes, and staining was performed using the follow-
ing antibodies: CD3 BV605 (SK7), CD4 V500 (RPA-T4), 
CD8 PerCP-Cy5.5 (RPA-T8), CD45RA APC-H7 (HI100), 
CD127 PE-Cy7 (HIL-7R-M21), CCR7 APC (3D12) and 
PD-1 PE (MIH4). To analyze follicular helper T cells, 
CD3 BV605 (SK7), CD4 V500 (RPA-T4), CXCR5 PerCP-
Cy5.5 (RF8B2) and PD-1 FITC (MIH4) were evaluated. 
Antibodies were purchased from BD Pharmingen (San 
Jose, CA, USA). Approximately 70  µL of whole blood 
was stained for 20  min and then incubated for 15  min 
with FACS lysing solution (BD FACS Lysing; BD Bio-
sciences, San Jose, CA) to lyse the erythrocytes. After 
two washes in an isotonic solution (Hemoton SPEC; Bra-
zil), 300,000 events were acquired using a flow cytometer 
(LSR Fortessa; BD Biosciences) and were analyzed using 
FlowJo Software (Tree Star, Ashland, OR, USA).Regula-
tory T cells were evaluated according to the instructions 
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for the FoxP3 staining kit (eBiosciences, San Diego, CA, 
USA).
Flow cytometry of in vitro TLR‑activated cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll-Hypaque density-gradient centrifuga-
tion (Amersham Pharmacia Biotech, NJ, USA) and were 
resuspended in RPMI 1640 (Gibco Invitrogen, Carlsbad, 
CA, USA) after two washes in medium supplemented 
with gentamicin (10 µg/mL) and 10 % AB human serum 
(Sigma-Aldrich, St Louis, MO, USA). PBMCs at 1.5 × 106 
cells/mL were incubated in 48-well plates (Costar, Cam-
bridge, MA, USA) with medium or with 5 µg/mL TLR2 
agonist (Pam3CSK4), 40  ng/mL TLR3 (Poly-RIG) ago-
nist or 5  µg/mL TLR7/8 (CL097) agonist (InvivoGen, 
San Diego, CA, USA) for 20  h or 1  µg/mL Staphylo-
coccus aureus enterotoxin B (SEB, Sigma-Aldrich), 10   
ng/mL phorbol myristate acetate (PMA) (Sigma-Aldrich) 
and 1  µg/mL ionomycin (Iono) (Sigma-Aldrich) for 
6 h at 37 °C in 5 % CO2. Brefeldin A (10 µg/mL, Sigma) 
was added to the cultures for the last 4  h. PBMC cul-
tures were washed and incubated with LIVE/DEAD Fix-
able Red Dead Cell Stain Kit (Invitrogen, Carlsbad, CA, 
USA) for 30 min at room temperature, followed by fixa-
tion with Cytofix/Cytoperm solution (BD Bioscience) for 
20  min and permeabilization with Perm/Wash solution 
for 20 min at 4 °C. The cells were then stained with CD3 
BV605 (SK7), CD4 V500 (RPA-T4), CD8 PerCP-Cy5.5 
(RPA-T8), CD38 Alexa Fluor 700 (HIT2), IFN-γ V450 
(B27), TNF Pe-Cy7 (Mab11), IL-10 APC (JES3-19F1), 
IL-17a Alexa Fluor 488 (eBiosciences) and IL-22 PE, 
(eBiosciences); unless otherwise mentioned, all antibod-
ies were purchased from BD Biosciences (San Jose, CA, 
USA). Next, the samples were washed with Perm/Wash 
buffer (BD Biosciences) and diluted in isotonic solution. 
A total of 500,000 events were acquired and analyzed 
by flow cytometry (LSR Fortessa, BD Biosciences, USA) 
using the FACS-Diva (BD Bioscience) and FlowJo10.0.6 
(Tree Star, Ashland, OR, USA) software programs. Fluo-
rescence Minus One (FMO) controls were performed for 
all antibody panels to check proper compensation and 
to define positive signals. Boolean gate arrays were cre-
ated using FlowJo software. These analyses determined 
the expression frequency of each cytokine based on all 
possible combinations of the five cytokines. Polychro-
matic flow cytometry data were analyzed with the SPICE 
Program (Version 2.9, Vaccine Research Center, NIAID, 
USA).
Statistical analysis
All cytokine measurements were background-sub-
tracted, taking into account the frequency of cells pro-
ducing cytokines in the absence of antigenic stimulation. 
The nonparametric Mann–Whitney test was used to 
compare variables of CVID and healthy controls. The 
comparison of the three groups healthy individuals 
(HC) versus CVID with and without splenomegaly was 
performed by Kruskal–Wallis test followed by Dunn’s 
multiple comparisons test. P ≤ 0.05 was considered sta-
tistically significant.
Results
Exhaustion/activation T cell markers and frequency 
of effector/regulatory T cells in CVID
To evaluate whether the activation of innate immu-
nity via TLR activation could enhance the adaptive 
response, we previously evaluated the activation/
exhaustion profiles of CD4+ and CD8+ T cells. Moreo-
ver, considering that IVIg treatment partially restores 
CD4+ T cell activation [17], we evaluated the markers 
related to exhaustion (programmed cell death, CD279, 
PD-1), resting/naïve status (interleukin (IL)-7 receptor 
alpha chain (CD127), and activation (CD38) at differ-
ent stages of T cell maturation as well as in regulatory 
T cells in the CVID and HC groups. The follicular T 
cells (CD4+ CXCR5+ PD-1+ ICOS+), which are special-
ized providers of T cell help to B cells and are essential 
for germinal center formation, were also evaluated in 
peripheral blood from the CVID and HC groups.
In the present study, 16 CVID patients and 16 HC were 
enrolled (Table 1). The percentage of B cells in the CVID 
patients was decreased compared to that in the HC group, 
with increased frequencies of naïve B cells and decreased 
memory B cells. Figure 1a shows an increased frequency 
of CD4+  PD-1+  T cells in CVID patients compared to 
HC individuals, whereas no difference was observed in 
CD8+ T cells. Evaluating CD4+ PD-1+ T cells according 
to T cell maturation stage, we found an increased fre-
quency of memory T cells in CVID patients, including the 
central memory (TCM) (CD45RA− CCR7+) and effector 
memory (TEM) stages (CD45RA− CCR7−). Considering 
the several clinical features frequently observed in CVID 
subjects and the fact that the factors that induce spleno-
megaly are not well known, we compared the immuno-
logic cellular markers of CVID patients with and without 
splenomegaly; however, we did not observe any differ-
ences between the groups. 
Moreover, decreased CD8+ CD127+ T cell percentages 
but not CD4+ T cell percentages (data not shown) were 
observed in CVID patients compared to HC (Fig. 1b). As 
expected in CVID, an increased frequency of activated 
CD8+ CD127− CD38+ T cells was verified in the termi-
nally differentiated effector memory (TEMRA) subset in 
CVID individuals with splenomegaly.
The frequency of peripheral blood follicular helper T 
cells (Tfh) (CD3+  CD4+  CXCR5+  PD-1+  ICOS+) was 
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similar between the HC and CVID groups (Fig.  1c). All 
CVID patients expressed ICOS.
The reduced frequency of Tregs in CVID patients and 
its association with autoimmunity as well as immune dys-
regulation has been previously reported [3, 18]. Thus, we 
analyzed the subpopulation of Tregs in CVID. The Treg 
cells have been subgrouped in three distinct subpopula-
tions as (i) CD45RA+  Foxp3low naïve Treg cells (nTreg 
cells), (ii) CD45RA− Foxp3high activated Treg cells (aTreg 
cells), both of which are suppressive in  vitro, and non-
suppressive cytokine-secreting CD45RA− Foxp3low T cells 
(non-Treg cells) [19, 20]. We found a decreased frequency 
of naïve Treg cells (CD45RA+ Foxp3low) in CVID patients 
compared to HC individuals. In addition, the decreased 
frequency of Treg cells was associated with splenomegaly 
in CVID patients compared to the HC group (Fig. 1d).
Collectively, these results show the presence of exhaus-
tion markers on CD4+ T cells, confirming previous 
data [17], and indicate that these markers are mainly 
expressed on memory subsets, such as TCM and TEM. 
As TCM cells can differentiate into TEM cells, the 
PD-1 on these subsets suggests the exhaustion of effec-
tor TCD4+ function. Additionally, CD8+ CD38+ T cells, 
which chronically activate TEMRA cells, and decreased 
CD127+ may, together, indicate an immunosenescence 
of CD8+ T cells in CVID. Moreover, Treg cell levels are 
reduced in CVID patients [17, 21], which we found to be 
associated with the naïve Treg subset, not the inducible 
subset at the periphery.
Impaired TLR responses by CD8+ T cells in CVID
Infections caused by viruses or bacteria are common fea-
tures in CVID. Because TLR stimulation using synthetic/
natural ligands may mimic extracellular and intracellu-
lar pathogens, we analyzed the effect of TLR activation 
by ligands on the secretion of cytokines by T cells. We 
assessed TLR2/Pam3CSK4, TLR3/Poly-RIG and TLR7/8/
CL097 agonists and used PMA/ionomycin as a nonspe-
cific activating control. The gating strategy is shown in 
Additional file 1.
Figure  2 shows that upon TLR3 activation, IFN-γ, 
IL-17a, IL-22, TNF or IL-10 secretion was observed in 
CD4+ T cells at similar levels in the CVID and HC groups. 
In contrast, a decreased frequency of CD8+ T cells secret-
ing IFN-γ, IL-17a or IL-22 was detected in the CVID group 
(Fig. 2a). Activation by PMA/ionomycin induced impaired 
IFN-γ, IL-17a, IL-22 and TNF but not IL-10 responses 
by CD4+ T cells in CVID compared to HC. Similarly, the 
CD8+ T cell cytokine response was decreased, including 
IL-10 secretion, in CVID patients (Fig. 2b).
These data show that CD8+ T cells are down-mod-
ulated by TLR3 stimulation. This finding indicates an 
impairment of CD8+ T cells in CVID, as TLR3 ligand is 
able to stimulate fully functional memory CD8 T cells in 
the absence of CD4+ T cells [22].
High frequency of circulating Th22/Tc22 upon TLR and SEB 
stimulation in CVID
The strategy to evaluate the secretion of IL-22, without 
the exclusion of other cytokines, includes other popula-
tions, such as Th17. We therefore analyzed excluding 
IFN-γ and IL-17 to consider Th22/Tc22 cells [23, 24] in 
the CVID and HC groups. The gating strategy for Th22 
and Tc22 is shown in Additional file 2.
Interestingly, we detected an increased baseline Th22 
frequency in CVID in comparison to HC (Fig.  3a). In 
addition, both Th22/Tc22 from CVID patients had an 
increased response to TLR7/8/CL097 agonists as well as 
to SEB (Fig.  3b); however, Th22 cells were decreased in 
CVID compared to HC subjects upon TLR3 activation. 
The strategy of Th22/Th22 evaluation may represent a 
different population due to the different results after TLR 
activation.
Polyfunctional CD4+ and CD8+ T cell responses to TLR 
activation in CVID
Polyfunctional T cells can provide more effective immune 
responses to pathogens than single cytokine-producing 
Table 1 Demographic data and  laboratory characteristics 
of studied CVID subjects
a Values are expressed as median with interquartile range
b Early onset was determined before 20 years-old and late onset after 20 years-old
c IgG levels during the IVIg treatment
Patients CVID CVID total (n = 16) HC total (n = 16)
Median agea 34.0 (22–65) 36 (21–65)
Gender (male/female) 10/6 7/9
Onset of disease (early/late)b 9/7
Autoimmunity  
manifestations (%)
19
Bronchiectasis (%) 62.5
Splenomegaly (%) 43.75
Lymphadenopathy (%) 1.5
GI symptoms (%) 25
Granulomas (%) 12.5
Cancer (%) 12.5
Median duration of IVIg 
(years)
9.0 (3–15)
Immunoglobulin G (mg/dL)c 771.5 (459–926)
Immunoglobulin A (mg/dL) 5 (0.2–29.4)
Immunoglobulin M (mg/dL) 10.2 (1.85–32.4)
B cells (CD3− CD19+) (%) 6.6 (4.58–10.13) 30.4 (9.68–40.98)
Naive B cells (IgD+ CD27−) 
(%)
88.9 (75.78–93.60) 36.65 (31.05–57.50)
Memory B cells 
(IgD− CD27+) (%)
1.63 (0.4–3.4) 17.75 (11.25–21.20)
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cells. We next evaluated the ability of cells to secrete IFN-
γ, IL-10, IL-17a, IL-22 and TNF upon TLR, PMA/iono-
mycin, or SEB stimulation. The gating strategy to detect 
simultaneous cytokine secretion in CD4+ and CD8+ 
T cells is shown in Additional file 3. Because a Boolean 
strategy generates several combinations, we present only 
the data with significant differences.
Overall, CD4+ T cells simultaneously secreting 4–5 
cytokines stimulated by TLR agonists or PMA/iono-
mycin were preserved in CVID (Fig.  4). The evaluation 
of polyfunctional cells secreting three cytokines indi-
cated an increased frequency of CD4+ T cells secreting 
IL-17a, IL-22 and TNF induced by TLR7/8/CL097 and 
TLR2/Pam3CKS4 in CVID compared to HC individu-
als. Similar to monofunctional CD4+ T cells activated 
by PMA/ionomycin, a decreased percentage of CD4+ T 
cells secreting four cytokines (IL-10, IL-17a, IL-22 and 
TNF) was also observed in CVID upon PMA/ionomycin 
stimulation.
Polyfunctional cells secreting five cytokines were bal-
anced in both groups, whereas CD8+  T cells secreting 
three cytokines in CVID were decreased in response 
to PMA/ionomycin (IFN-γ, IL-10, IL-22) as well as SEB 
(IFN-γ, IL-17a, IL-22) (Fig.  4b). These data show that 
TLR activation induces polyfunctionality only in CD4+ T 
cells in CVID, and there is a disturbed PMA/ionomycin 
response by both CD4+ and CD8+ T cells.
To further analyze T cell activation, we evaluated 
polyfunctionality (IFN-γ, IL-10, IL-17a, IL-22 and 
TNF) in CD38+ T cells. The gating strategy is shown in 
Fig. 1 Altered exhaustion/activation marker expression on T cells and frequency of regulatory T cells in CVID. PBMCs from healthy control (HC, 
n = 16) and CVID patients (n = 14) were assessed for (a) PD‑1 and (b) CD127 expression in CD4+ and CD8+ T cells, according to the maturation 
stage, and for the presence (+) or absence (−) of splenomegaly (spl); (c) follicular T cells (CD3+ CD4+ CXCR5+ PD‑1+ ICOS+) and (d) naïve regula‑
tory T cells (CD3+ CD4+ CD45RA+ Foxp3+) were determined by flow cytometry. Data represent the median and the interquartile range. *p ≤ 0.05, 
**p ≤ 0.001, ***p ≤ 0.0001
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Additional file 3. Figure 5a shows that CD38+ CD4+ T 
cells had decreased secretion of 4-cytokine combina-
tions in CVID, whether induced by TLR7/8-CL097 or 
PMA/ionomycin. Polyfunctional CD38+  CD4+ T cells 
secreting five cytokines (IFN-γ, IL-17a, IL-22, TNF and 
IL-10) in response to SEB were observed in CVID. Curi-
ously, among CD4+ CD38− T cells, the PMA response 
for 4-cytokine combinations (IFN-γ, IL-10, IL-17a, and 
TNF) was maintained in CVID. The decreased poly-
functional response to TLR activation by CD8+ T cells 
was found in both CD38+and CD38− T cell subsets 
(Fig.  5b). These data showed that CD4+CD38− T cells 
induced by PMA/ionomycin are able to simultaneously 
secrete four cytokines (IFN-γ, IL-17a, IL-22, and TNF) 
in CVID, whereas polyfunctionality was decreased in 
CD8+ T cells.
Fig. 2 Altered cytokine response by CD8+ T cells upon TLR3 stimulation and in response to PMA/ionomycin in CVID. PBMCs from healthy controls 
(HC, n = 16) and CVID patients (n = 16) were cultivated with medium (baseline) or (a) TLR‑3 agonist (Poly‑RIG) for 20 h or (b) PMA/ionomycin for 
6 h. CD4+ and CD8+ T cells secreting IFN‑γ, IL‑17a, IL‑22, TNF and IL‑10 were assessed by flow cytometry. Frequencies of stimulated CD4+ CD8+ T 
cells were subtracted from baseline values. Data represent the median and the interquartile range. *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0001
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Fig. 3 Presence of circulating Th22 and Tc22 cells in CVID patients. PBMCs from healthy controls (HC, n = 16) and CVID patients (n = 16) were culti‑
vated with medium (baseline) or agonists of TLR3 (Poly‑RIG) and TLR7/8 (CL097) for 20 h or SEB for 6 h and assessed by flow cytometry. a Th22 and 
b Tc22 cell frequencies were obtained by excluding IFN‑γ and IL‑17a. Data represent the median and the interquartile range. *p ≤ 0.05, **p ≤ 0.01
Fig. 4 Activation by TLR agonists induces polyfunctional CD4+ T cells in CVID. The combinations of IFN‑γ, IL‑10, IL‑17a, IL‑22 and TNF secreted by 
(a) CD4+ and (b) CD8+ T cells induced by TLR2 (Pam3CSK4), TLR7/8 (CL097), PMA/ionomycin or SEB from HC (n = 16) and CVID (n = 16) individuals 
were derived from a Boolean strategy. Frequencies of stimulated CD4+ or CD8+ T cells were subtracted from baseline values. Data represent the 
median and the interquartile range. *p ≤ 0.05
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Our findings show that monofunctional or polyfunc-
tional cytokines by CD8+  T cells are impaired upon 
innate stimulation in CVID, in contrast to the preserved 
function of polyfunctional CD4+ T cells.
Discussion
CVID patients present recurrent bacterial infections, and 
a significant proportion develop autoimmune, inflam-
matory or lympho proliferative complications. The acti-
vation of innate immunity through TLRs by synthetic 
ligands may mimic PAMPs from bacteria or viruses, and 
these effects on T cells have not been well explored. Our 
data confirm the up-regulation of activation/exhaustion 
markers in T cells in CVID, occurring in both central and 
effector memory T cells. Moreover, decreased regulatory 
T cells occur in naïve regulatory T cells. The CD8+ T cells 
present impaired TLR activation responses, an increase 
in CD38 expression in the TEMRA subset, and decreased 
CD127+, indicating an immunosenescence phenotype of 
CD8+ T cells in CVID patients. However, TLR7/TLR8 
agonists stimulated Th22/Tc22 cells. Activation with 
TLR2 and TLR7/8 agonists induced a polyfunctional 
response only in CD4+ CD38− T cells. These data show 
a potential role for TLR ligands as adjuvants to stimulate 
adaptive T cell responses, and they provide evidence for 
a CD8+ T cell population that is unresponsive to innate 
stimuli in CVID.
The increased expression of the exhaustion marker 
PD-1+ in CD4+ T cells was confirmed as described 
[17], occurring in the TEM and TCM subsets in CVID 
patients despite long-term IVIg treatment. The dura-
tion of IVIg treatment in CVID patients was 9.0 [3–15] 
years. In parallel, an increased frequency of activated 
CD8+ CD127− CD38+ T cells was detected in terminally 
differentiated CD8+ TEMRA. The activation and exhaus-
tion markers in CVID have been associated with immune 
system aging [17]. In this context, our findings confirm 
immunosenescence features in CVID [21] but reveal that 
T cell exhaustion was related to the CD4+ TEM subset 
and T cell activation of the terminally differentiated T 
cells.
We also observed that exhaustion and activation 
markers in CD4+ and CD8+ T cells, respectively, do 
not seem to be associated with splenomegaly, a pre-
dominant clinical feature of CVID (43.7  % of selected 
patients). Tregs are crucial to control immune responses 
Fig. 5 Impaired CD38− or CD38+ CD8+ T cell polyfunctionality induced by SEB in CVID. The combinations of IFN‑γ, IL‑10, IL‑17a, IL‑22, and TNF 
secreted by (a) CD4+ and (b) CD8+ T cells in the presence or absence of CD38 expression, induced by TLR2 (Pam3CSK4), TLR3 (Poly‑RIG), TLR7/8 
(CL097), PMA/ionomycin or SEB, from HC (n = 16) and CVID (n = 16) individuals were evaluated by a Boolean strategy. Frequencies of stimulated 
CD4+ or CD8+ T cells were subtracted from baseline values. Data represent the median and the interquartile range. *p ≤ 0.05
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and limit persistent immune activation [25]. Stratify-
ing CVID patients by splenomegaly showed an associa-
tion with a low percentage of naïve Treg cells. Of naïve 
and peripherally induced Treg, only naïve Treg showed a 
decreased frequency in CVID. CVID patients with auto-
immunity and/or splenomegaly had a reduced frequency 
of CD4+  CD25hi Tregs, which was more accentuated in 
those with splenomegaly; additionally, they were associ-
ated with CD21low B cell expansion [3]. A subgroup of 
CVID patients with CD21low B cell expansion showed 
increased incidence of splenomegaly and autoimmune 
cytopenia [18]. In our CVID cohort, we found an auto-
immune phenotype in 19 % of patients and splenomegaly 
in 25 % of patients. Our findings confirm the decrease in 
Tregs in CVID; despite long-term IgG replacement, this 
therapy could not control the naïve Treg cells in CVID 
patients with splenomegaly, suggesting that Tregs are 
essential to limit persistent immune activation. In our 
cohort of CVID patients, we found an unusual frequency 
of splenomegaly reaching 50 %, whereas evaluation of the 
whole cohort of patients resulted in an observed 25  % 
frequency of splenomegaly, as reported by Gathmann 
et al. [26].
Passive immunotherapy with IVIg in CVID can par-
tially restore the CD4+ T cell compartment and reduce 
CD8+ T cell activation [17]. Moreover, the CD4+PD-1+ 
T cell exhaustion and functional impairment observed 
in CVID patients seems to be associated with bacterial 
translocation, and IVIg treatment decreases bacterial 
translocation, restoring CD4+ T cell functions [11]. Inter-
estingly, bacteria-specific but not virus-specific CD4+ 
T cells express higher levels of PD-1 [11]. Curiously, we 
observed that the TLR4-mediated cytokine response by 
CD4+ T cells was unaltered in CVID patients (data not 
shown), whereas intracellular TLR3/Poly-RIG activa-
tion led to decreased IFN-γ, IL-17a and IL-22 responses 
by CD8+ T cells but not CD4+ T cells. In fact, the TLR3 
pathway is of paramount importance to stimulate the 
secretion of type I IFNs through IRF3. TLR3 signaling 
defects are associated with specific susceptibility to her-
pes simplex virus type 1 encephalitis [27].
The investigation of TLR activation in CVID patients 
is primarily related to determining the effects among B 
cells. CVID patients show defective TLR7 and TLR9 
signaling in B cells and pDCs [6]. These TLR defects in 
CVID are restricted because PBMCs stimulated with 
TLR ligands produce normal amounts of TNF-α, IL-6, 
and IL-12 [6]. In our CVID patients, activation via TLR7/
TLR8 caused an in  vitro expansion in circulating Th22/
Tc22 cells. It is possible that TLR8 activation overcomes 
the TLR7 defects. CL097, an agonist of TLR7/TLR8, is 
an important adjuvant to stimulate the antiviral response 
[28, 29]. It is possible that the increased frequency of 
Th22/Tc22 cells in response to TLR7/8 in CVID con-
tributes to mucosal protection. In fact, IL-22 at mucosal 
surfaces provides innate immune protection against bac-
terial and fungal infections and promotes inflammation 
and epithelial proliferation and repair [30, 31]. Sigmoid 
IL-22-producing T cells and Th22 cells are dramatically 
depleted during chronic HIV infection, and this deple-
tion contributes to epithelial damage and microbial 
translocation [32]. It is important to stress that CVID 
patients are prone to inflammatory bowel disease and 
present lymphoid nodular hyperplasia throughout the 
gastrointestinal (GI) tract, which is clear evidence of 
chronic activation of the GI immune system. If the acti-
vation/exhaustion of T cells could be associated with 
bacterial translocation in CVID [11], Th22/Tc22 activa-
tion by TLR7/8 stimulation may be an interesting strat-
egy to potentiate their functional response.
Despite the immunomodulatory role of TLR agonists 
in T cells, the CD4+/CD8+ T cell response to PMA/iono-
mycin was impaired in CVID. PMA/ionomycin-mediated 
activation of NFAT signaling may mimic full activation 
by TCR signaling and costimulation or anergy [33]. The 
involvement f Ca2+ T cell signaling in CVID has yet to be 
further investigated.
Although innate immunity may constitute the pri-
mary functions of TLRs, their role in T cells is less well 
known. The in vitro activation of PBMCs with TLR ago-
nists may activate APCs and indirectly lead to T cell acti-
vation. However, TLRs can be expressed in T cells [34] 
and serve as costimulatory signals in T cell activation [35, 
36]. TLR2 serves as a costimulatory receptor for antigen-
specific T cell development and participates in the main-
tenance of T cell memory [14]. These findings suggest 
that pathogens may contribute directly to the perpetua-
tion and activation of long-term T cell memory in both 
an antigen-dependent and independent manner.
Polyfunctionality is the ability to produce multiple 
cytokines, which has been associated with beneficial 
immune responses. As we observed the exhaustion/acti-
vated profiles of CD4+ T cells and CD8+ T cells in CVID, 
we next evaluated their ability to secrete several cytokines 
upon TLR activation. CD4+ and CD8+ T cells preserved 
their ability to secrete five TLR-induced cytokines in 
CVID, although CD8+ T cells were less polyfunctional 
than CD4+ T cells. Both extracellular (TLR2/Pam3CKS4) 
and intracellular TLR agonists (TLR7/8/CL097) induced 
CD4+ T cells to secrete three cytokines in CVID, includ-
ing IL-17a, IL-22 and TNF. TLR2 stimulation drives 
human naïve and effector regulatory T cells into a Th17-
like phenotype with reduced suppressive function [37]. 
Polyfunctionality was related to CD4+CD38− T cells in 
response to TLR activation in CVID, whereas CD8+  T 
cells were unresponsive. These data suggest an altered 
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CD8+  T cell response to TLR activation in CVID, in 
either a monofunctional and polyfunctional function.
Conclusions
Our findings show that despite the long duration of IVIg 
replacement, CVID patients have altered responses to 
TLR activation, mainly among CD8+ T cells. Activation 
with TLR2 and TLR7/8 agonists induced a polyfunctional 
CD4+ T cell response, which was impaired in CD4+CD38+ 
T cells. These data show a potential role for TLR7/TLR8 
ligands as adjuvants to stimulate adaptive T cell responses, 
and they provide evidence for a CD8+ T cell population 
that is unresponsive to innate stimuli in CVID.
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